stockrow
Saturday 7 November 2026
Export BDRX’s income statement to Excel — free account
Biodexa Pharmaceuticals PLC Unsponsored ADR
BDRX Healthcare Biotechnology
Biodexa Pharmaceuticals PLC Unsponsored ADR’s revenue for fiscal 2023 (year ended December 2023) was $473,900.00, down 45.2% from fiscal 2022.
2.48
0.07
+2.90%
Follow BDRX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 9 | 10 | 3 | 1 | 0 | 1 | 1 | 0 | — | — | 1 | (34.7%) | — | — | — | — | |
| Gross margin, % | 90.37 | 87.81 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | — | — | 0.00 | +9.6 pt | ||||||
| EBT | (40) | (22) | (17) | (14) | (30) | (8) | (10) | (9) | (8) | (9) | (19) | (15.7%) | ||||||
| EBT margin, % | (423.55) | (228.07) | (639.84) | (1,620.68) | (6,842.76) | (1,056.42) | (1,214.30) | (1,964.68) | 0.00 | 0.00 | (1,287.41) | +423.6 pt | ||||||
| Net income | (27) | (21) | (20) | (13) | (28) | (8) | (9) | (9) | (7) | (8) | (23) | (12.3%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.52 | 0.38 | 8,464,659.69 | 469,477.93 | 0.05 | 0.05 | 0.87 | 4,739.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (1.51) | (0.81) | (65,715,307.02) | (7,024,612.63) | (3.33) | (0.47) | (9.58) | (13,940.62) | (5,912.71) | (613.82) | (2.55) | +94.9% | ||||||
| Cash flow | (0.98) | (0.65) | (58,747,054.97) | (4,520,102.56) | (1.39) | (0.51) | (8.82) | (84,909.00) | (13,056.92) | (538.17) | 0.00 | +101.5% | ||||||
| Capex | (0.10) | (0.07) | (956,479.06) | (222,191.92) | (0.01) | (0.02) | (0.05) | (3,222.00) | (824.25) | (64.78) | 0.00 | +104.7% | ||||||
| Free cash flow | (1.09) | (0.73) | (59,703,534.03) | (4,742,294.47) | (1.40) | (0.54) | (8.87) | (88,131.00) | (13,881.17) | (602.95) | 0.00 | +101.8% | ||||||
| Book value | 3.44 | 1.74 | 73,920,811.52 | 13,623,697.56 | 1.01 | 0.89 | 3.96 | 58,190.00 | 8,862.25 | 1,097.80 | 0.00 | +89.8% | ||||||
| Shares, m | 18 | 26 | 0 | 0 | 9 | 16 | 1 | 0 | 0 | 0 | — | (55.0%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.0 | |||||
| P/S | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.0 | ||||||
| P/B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.0 | ||||||
| EV/Sales | 0.00 | 0.00 | 0.00 | 0.00 | (14.51) | (12.26) | (1.67) | (4.70) | — | — | (2.81) | (4.1) | ||||||
| EV/FCF | 0.34 | 0.14 | 0.02 | 0.14 | 0.26 | 0.37 | 0.10 | 0.26 | — | — | 0.12 | 0.2 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (18) | (17) | (18) | (8) | (12) | (8) | (9) | (8) | (16) | (7) | (34) | (9.3%) | |||||
| Capex | (2) | (2) | 0 | 0 | 0 | 0 | 0 | 0 | (1) | (1) | 0 | (7.8%) | ||||||
| Free cash flow | (20) | (19) | (18) | (9) | (12) | (9) | (9) | (9) | (17) | (8) | (34) | (9.1%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 18 | 13 | 4 | 10 | 8 | 14 | 3 | 2 | 5 | 8 | 5 | (8.0%) | |||||
| Net debt | (21) | (9) | (1) | (6) | (9) | (13) | (3) | (7) | (1) | (11) | (4) | (6.7%) | ||||||
| Shareholders’ equity | 62 | 45 | 23 | 25 | 9 | 14 | 4 | 6 | 11 | 15 | 13 | (14.6%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (31.27) | (29.52) | (44.22) | (38.59) | (109.46) | (49.46) | (77.02) | (88.29) | (45.76) | (39.28) | 0.00 | (8.0) pt | |||||
| ROIC | (63.14) | (39.21) | (46.64) | (48.08) | 0.00 | (376.70) | (587.61) | 0.00 | (77.90) | (184.28) | 0.00 | (121.1) pt | ||||||
| ROE | (40.89) | (38.82) | (59.64) | (54.15) | (169.59) | (65.29) | (103.59) | (181.00) | (88.99) | (65.58) | 0.00 | (24.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 79 | 85 | 73 | 65 | 18 | 20 | 27 | 21 | 13 | 11 | — | (19.7%) | |||||
| Revenue/emp, $m | 0.12 | 0.12 | 0.04 | 0.01 | 0.02 | 0.04 | 0.03 | 0.02 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2023 · fundamentals updated 2 Nov 2026
Biodexa Pharmaceuticals PLC Unsponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ABPO Abpro Holdings Inc. | $1.4M | 0.5× | — | — | n/m | −0.48% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KPTI Karyopharm Therapeutics Inc. | $1.4M | — (loss-making) | — (loss-making) | −11.86% (below 0%: shrinking) | n/m | −33.34% (below 0%: shrinking) | 96.75% | (67.38%) | Compare |
| ELAB PMGC Holdings Inc. | $1.3M | — (loss-making) | — | +147.70% (above 0%: growing) | n/m | −44.95% (below 0%: shrinking) | 29.52% | (292.91%) | Compare |
| LABT Lakewood-Amedex Biotherapeutics Inc. | $1.3M | — (loss-making) | — | — | n/m | −420.66% (below 0%: shrinking) | — | 0.00% | Compare |
| PTIX Atrinsic Inc. | $1.3M | 0.2× | — | +34.31% (above 0%: growing) | n/m | +46.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR | $1.3M | — (loss-making) | — | −32.27% (below 0%: shrinking) | +96.36% (above 0%: growing) | −0.17% (below 0%: shrinking) | 0.00% | 0.00% | |
| ARTL Artelo Biosciences, Inc. | $1.2M | — (loss-making) | — | — | n/m | −879.18% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| MTNB Matinas Biopharma Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | 0.00% | n/m | +9.15% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BBLG Bone Biologics Corp. | $1.1M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $1.3M | — | — | +17.16% | — | −16.91% | 14.76% | 0.00% |